Earnings Call Summary | American Shared Hospital Services(AMS.US) Q1 2024 Earnings Conference
Earnings Call Summary | American Shared Hospital Services(AMS.US) Q1 2024 Earnings Conference
The following is a summary of the American Shared Hospital Services (AMS) Q1 2024 Earnings Call Transcript:
以下是美國共享醫院服務（AMS）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
American Shared Hospital Services reported a Q1 2024 revenue of $5.2 million, marking a 5.9% increase from the same period last year.
Gross margin rose by 12.3% to $2.1 million, representing a 41% gross margin percentage.
Net income for the quarter came in at $119,000 or $0.02 per share, as opposed to $188,000 or $.03 per share in Q1 2023.
美國共享醫院服務報告稱，2024年第一季度收入爲520萬美元，比去年同期增長5.9％。
毛利率增長了12.3％，達到210萬美元，毛利率爲41％。
該季度的淨收入爲11.9萬美元，合每股收益0.02美元，而2023年第一季度爲18.8萬美元，合每股收益0.03美元。
Business Progress:
業務進展：
AMS acquired three radiation therapy centers in Rhode Island in Q1, leading to a boost in revenue.
Greg Mercurio was appointed the Senior Vice President of Radiation Oncology.
There were improvements seen in patient experience and volume in Peru and Ecuador sites, but others saw a slight dip in revenue due to equipment upgrades.
Company plans to inaugurate a new center in Puebla, Mexico in the next 60 days, with further expansion strategies to develop proton beam and radiation oncology centers in the U.S.
The company has applied to run a proton beam radiation therapy center in Rhode Island.
Leasing revenue increased by 0.6%, and revenue from the retail segment saw a significant increase due to improved service offerings in Peru and Ecuador.
Future growth is expected from further recruitment and relationship building efforts.
AMS在第一季度收購了羅德島的三個放射治療中心，從而增加了收入。
格雷格·默庫里奧被任命爲放射腫瘤學高級副總裁。
秘魯和厄瓜多爾基地的患者體驗和數量有所改善，但由於設備升級，其他地區的收入略有下降。
公司計劃在未來60天內在墨西哥普埃布拉開設一個新中心，並進一步擴大擴張戰略，在美國開發質子束和放射腫瘤學中心。
該公司已申請在羅德島州經營質子束放射治療中心。
租賃收入增長了0.6％，由於秘魯和厄瓜多爾提供的服務有所改善，零售部門的收入大幅增長。
未來的增長預計將來自進一步的招聘和關係建設工作。
More details: American Shared Hospital Services IR
更多詳情： 美國共享醫院服務 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。